HBV News and Research

RSS

PNAS publishes results of pilot study for early detection of liver cancer

Today, Proceedings of the National Academy of Sciences published the results of a pilot study for early detection of liver cancer in a cohort of HBV carriers, who are at risk for developing this disease.

13 Mar 2019

FDA grants clearance to Hologic’s assay for detection of common sexually transmitted infections

Hologic, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted clearance for its Aptima Mycoplasma genitalium assay, the first and only FDA-cleared test to detect this under-recognized but increasingly common sexually transmitted infection (STI).

23 Jan 2019

ECDC and WHO release latest data on HIV epidemic in the European Region

The European Centre for Disease Prevention and Control and the WHO Regional Office for Europe release the latest data on the HIV epidemic in the European Region, marking the 30th anniversary of World AIDS Day.

29 Nov 2018

First modeling system developed for testing age-specific human immune responses to vaccines

A team of scientists at Boston Children's Hospital has developed the first modeling system for testing age-specific human immune responses to vaccines -- outside the body. The practical, cost-effective new platform, using all human components, is expected to accelerate and de-risk the development, assessment and selection of vaccines.

20 Nov 2018

NIH researchers shed light on causes of HBV-associated acute liver failure

National Institutes of Health scientists and their collaborators found that hepatitis B virus-associated acute liver failure--a rare condition that can turn fatal within days without liver transplantation--results from an uncommon encounter between a highly mutated HBV variant and an unusual immune response in the patient's liver that is mainly sustained by antibody-producing B cells.

14 Nov 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

Research reveals high stability of hepatitis B viruses

At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

30 Oct 2018

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.

22 Oct 2018

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced that the China National Medical Products Administration approved the kinase inhibitor LENVIMA (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

24 Sep 2018

Harbour Biomed and Kelun-Biotech collaborate to develop, commercialize anti-PD-L1 antibody

Harbour BioMed today announced it has entered into an exclusive strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to develop and commercialize A167, an anti-PD-L1 antibody in Phase 2 clinical development, worldwide outside of the Greater China region.

20 Aug 2018

Researchers provide new insight on origins and global spread of HBV

Researchers have provided new insight on the geographical origins and global spread of two classes of the hepatitis B virus (HBV), according to a study in eLife.

7 Aug 2018

New machine learning framework predicts effects of genetic mutations in ‘dark matter’ regions

A new machine learning framework, dubbed ExPecto, can predict the effects of genetic mutations in the so-called "dark matter" regions of the human genome.

17 Jul 2018

Researchers develop inexpensive blood test to diagnose hepatitis B patients

A simple $20 blood test could help diagnose thousands of patients with hepatitis B in need of treatment in some of Africa's poorest regions.

2 Jul 2018

Mathematical model assesses efficacy, cost-effectiveness of screening strategies for HCV

It is currently recommended in Europe that screening for hepatitis C virus should target people at high risk of infection.

2 Jul 2018

Scientists find how immune system helps to clear HBV infection after treatment interruption

Scientists from Karolinska Institutet and Hannover Medical School have published two studies that provide insights into how the immune system responds and helps to clear a hepatitis B infection after treatment interruption.

17 May 2018

Phase 1/2 study evaluates safety, tolerability of multiple-ascending doses of ARO-HBV in hepatitis B patients

Arrowhead Pharmaceuticals Inc. today announced that it has dosed the first 3 hepatitis B virus patients in the multiple-ascending dose portion of its ongoing Phase 1/2 study of ARO-HBV, the company's third generation subcutaneously administered RNA interference therapeutic being developed as a potentially curative therapy for patients with chronic HBV infection.

14 May 2018

Many European countries lack comprehensive policy to eliminate viral hepatitis

Many European countries lack a comprehensive policy to eliminate viral hepatitis as a major public health threat, according to a patient group-based survey implemented in 25 countries.

18 Apr 2018

New, sensitive HBV assay may allow earlier detection of hepatocellular carcinoma

Chronic hepatitis B virus (HBV) can progress to cirrhosis and hepatocellular carcinoma (HCC). A study published in The Journal of Molecular Diagnostics describes a new HBV assay that offers advantages over currently used methods because it has the capability to detect closed circular DNA (cccDNA) in serum, single cells, and preserved tissue samples.

12 Apr 2018

4 in 10 cancers preventable by adopting simple lifestyle changes

In a new research that comes via the American Cancer Society, it has been seen that over 40 percent of all cancers and nearly one in two cancer deaths can be prevented by incorporating simple lifestyle changes in daily routines.

26 Nov 2017

Texas Biomedical Research Institute tests promising new treatment for HBV infection

Research at the Southwest National Primate Research Center on the campus of Texas Biomedical Research Institute helped advance a new treatment now in human trials for chronic hepatitis B virus (HBV) infection.

7 Nov 2017